Medivir Yönetim

Yönetim kriter kontrolleri 1/4

Medivir CEO'su Jens Lindberg, Jan2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı SEK 7.82M olup, şirket hissesi ve opsiyonları dahil olmak üzere 32.8% maaş ve 67.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.15% ine doğrudan sahiptir ve bu hisseler € 40.42K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4 yıl ve 1.3 yıldır.

Anahtar bilgiler

Jens Lindberg

İcra Kurulu Başkanı

SEK 7.8m

Toplam tazminat

CEO maaş yüzdesi	32.8%
CEO görev süresi	2.8yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	4yrs
Yönetim Kurulu ortalama görev süresi	1.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jens Lindberg'un ücretlendirmesi Medivir'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-SEK 117m
Jun 30 2024	n/a	n/a	-SEK 106m
Mar 31 2024	n/a	n/a	-SEK 97m
Dec 31 2023	SEK 8m	SEK 3m	-SEK 89m
Sep 30 2023	n/a	n/a	-SEK 87m
Jun 30 2023	n/a	n/a	-SEK 78m
Mar 31 2023	n/a	n/a	-SEK 75m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 89m

Tazminat ve Piyasa: Jens 'nin toplam tazminatı ($USD 716.38K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 475.63K ).

Tazminat ve Kazançlar: Jens şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jens Lindberg (53 yo)

2.8yrs

Görev süresi

SEK 7,824,000

Tazminat

Mr. Jens Lindberg serves as Independent Director of BrainCool AB (publ) from June 26, 2024. He serves as Chief Executive Officer at Medivir AB (publ) since January 24, 2022. He served as Acting Chief Execu...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jens Lindberg	Chief Executive Officer	2.8yrs	SEK 7.82m	0.15% € 40.4k
Magnus Christensen	Chief Financial Officer	5.3yrs	SEK 2.66m	0.081% € 22.0k
Fredrik Öberg	Chief Scientific Officer	5.2yrs	Veri yok	0.11% € 30.0k
Pia Baumann	Chief Medical Officer	1.8yrs	Veri yok	0.086% € 23.2k
Karin Tunblad	Senior Principal Scientist & MIV-818 Project Leader	no data	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: MVR0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Lennart Hansson	Independent Director	6.5yrs	SEK 260.00k	0.036% € 9.7k
Uli Hacksell	Chairman of the Board	6.5yrs	SEK 690.00k	0.89% € 242.0k
Yilmaz Mahshid	Director	3.5yrs	SEK 260.00k	0.045% € 12.1k
Jeong-Woo Heo	Member of Scientific Advisory Council	1.3yrs	Veri yok	Veri yok
Bengt Westermark	Independent Director	7.5yrs	SEK 260.00k	0.029% € 7.7k
Jeffrey Evans	Member of Scientific Advisory Council	1.3yrs	Veri yok	Veri yok
Richard Finn	Member of Scientific Advisory Council	1.3yrs	Veri yok	Veri yok
Maria Reig	Member of Scientific Advisory Council	1.3yrs	Veri yok	Veri yok
Arndt Vogel	Member of Scientific Advisory Council	1.3yrs	Veri yok	Veri yok
Anna Torner	Director	less than a year	Veri yok	Veri yok
Angelica Loskog	Director	less than a year	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

74yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MVR0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Medivir Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Medivir AB (Publ) Appoints Nomination Committee

Medivir Aktiebolag (publ) Approves Board Appointments

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

High number of new and inexperienced directors

Medivir AB Announces Formation of A Scientific Advisory Council

Recent updates

Medivir AB Announces Finalisation of the Phase 1B/2A Study of fostroxacitabine bralpamide

Third quarter 2024 earnings released: kr0.30 loss per share (vs kr0.42 loss in 3Q 2023)

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.48 loss in 2Q 2023)

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

New major risk - Financial position

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Medivir Aktiebolag (publ) Approves Board Appointments

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.34 loss in 1Q 2023)

Full year 2023 earnings released: kr1.22 loss per share (vs kr1.59 loss in FY 2022)

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.27 loss in 3Q 2022)

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.48 loss per share (vs kr0.41 loss in 2Q 2022)

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Medivir AB Announces Patent Application for Fostrox Approval in China

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Full year 2022 earnings released: kr1.59 loss per share (vs kr1.20 loss in FY 2021)

Forecast to breakeven in 2024

Less than half of directors are independent

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

New 90-day low: €0.79

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

New 90-day low: €0.80

Medivir AB (Publ) Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation

New 90-day low: €1.10

New 90-day low: €1.24

Third quarter 2020 earnings released: EPS kr0.19

Medivir AB (publ) to Report Q1, 2021 Results on Apr 28, 2021

New 90-day low: €1.27

Medivir AB (Publ) Appoints Tom Morris as Interim Chief Medical Officer

Medivir AB (publ) to Report Q2, 2020 Results on Aug 20, 2020

Medivir AB (publ) to Report Fiscal Year 2020 Results on Feb 15, 2021

Earnings released